Skip to main content

Market Overview

MindMed Stock Moves Higher After Finalizing Generalized Anxiety Disorder As Initial Indication For LSD Trial

Share:
MindMed Stock Moves Higher After Finalizing Generalized Anxiety Disorder As Initial Indication For LSD Trial
  • After receiving Type C Meeting Responses from the FDA, MindMed (NASDAQ: MNMD) has selected Generalized Anxiety Disorder as an initial indication for its Project Lucy, evaluating LSD.
  • The company is on target to formally submit its Investigational New Drug (IND) application for Project Lucy in Q3 and expects to launch its Phase 2b trial after that in Q4 2021.
  • The clinical development program is scheduled to advance in late 2021 with the launch of Study MMED008, a Phase 2b dose-optimization study of LSD in approximately 200 patients diagnosed with Generalized Anxiety Disorder.
  • Price Action: MNMD shares are up 4.93% at $3.39 on the last check Monday.
 

Related Articles (MNMD)

View Comments and Join the Discussion!

Posted-In: Briefs Investigational New Drug ApplicationBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com